Deals confirmed high confidence

Chai Discovery closes $400M Series C at $3.8B

AI drug-discovery startup Chai Discovery closed a $400M Series C at a $3.8B valuation led by Index Ventures, with Sequoia, Dimension, Kleiner Perkins and others; Novartis partnership context.

On 2026-07-13, the verified AI news record added a significant funding, m&a & markets development: AI drug-discovery startup Chai Discovery closed a $400M Series C at a $3.8B valuation led by Index Ventures, with Sequoia, Dimension, Kleiner Perkins and others; Novartis partnership context.

Context

AI drug-discovery startup Chai Discovery closed a $400M Series C at a $3.8B valuation led by Index Ventures, with Sequoia, Dimension, Kleiner Perkins and others; Novartis partnership context. ~3x valuation in seven months as Chai-3 moves into pharma production; Dimension was a 2024 seed co-lead (links to D2). Deal.

What changed

AI drug-discovery startup Chai Discovery closed a $400M Series C at a $3.8B valuation led by Index Ventures, with Sequoia, Dimension, Kleiner Perkins and others; Novartis partnership context. According to Crunchbase News weekly roundup; Dimension Capital TechCrunch profile; chatforest review, the supporting record states: “AI drug discovery startup Chai Discovery secured $400 million in Series C funding at a $3.8 billion valuation. Index Ventures led the financing, investing alongside Sequoia Capital, Dimension, Kleiner Perkins and others." (Crunchbase News)”.

Why it matters

~3x valuation in seven months as Chai-3 moves into pharma production; Dimension was a 2024 seed co-lead (links to D2). Deal. The deal matters because it shows where investors and strategic buyers see durable AI demand, and because the terms provide a market signal that product announcements alone do not.

Deal box

Details

The research file records the item under “Chai Discovery closes $400M Series C at $3.8B” with source timing of Week of July 13–17, 2026. The captured research confidence note is: High. Additional captured source links are listed below so readers can inspect the evidence trail rather than rely on a single summary. ~3x valuation in seven months as Chai-3 moves into pharma production; Dimension was a 2024 seed co-lead (links to D2). Deal.

Limitations and caveats

The research file did not identify a blocking caveat, but vendor-supplied claims should still be read as company statements unless independently confirmed.

Sources

Update note: Last reviewed 2026-07-22. Next checkpoint: monitor official channels and the linked source record.

Sources

Drafted with AI assistance from source briefs; reviewed for citation completeness and label accuracy.